Olema Pharmaceuticals, Inc.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

OLMA$7.27-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Amounts in thousands, except for share and per share amounts)

Three Months Ended June 30, · Six Months Ended June 30,
2026 · 2025 · 2026 · 2025
Operating expenses:
Research and development	$	57,785	$	43,902	$	107,017	$	74,526
General and administrative		9,394		3,962		18,148		8,211
Total operating expenses		67,179		47,864		125,165		82,737
Loss from operations		(67,179)		(47,864)		(125,165)		(82,737)
Other income:
Interest income		4,507		4,042		9,283		8,566
Other (loss) income		(528)		38		(407)		(2)
Total other income		3,979		4,080		8,876		8,564
Net loss	$	(63,200)	$	(43,784)	$	(116,289)	$	(74,173)
Net loss per share, basic and diluted	$	(0.61)	$	(0.51)	$	(1.12)	$	(0.87)
Weighted average shares used to compute net loss per share, basic and diluted		104,453,732		85,497,426		103,631,483		85,462,021

Three Months Ended June 30, · Six Months Ended June 30,
2026 · 2025 · 2026 · 2025
Net loss	$	(63,200)	$	(43,784)	$	(116,289)	$	(74,173)
Other comprehensive (loss) income:
Net unrealized (loss) gain on marketable securities		(487)		(106)		(1,568)		171
Total comprehensive loss	$	(63,687)	$	(43,890)	$	(117,857)	$	(74,002)

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income (Loss) · Deficit · Equity
Balances at March 31, 2026	87,332,971	$	8	$		1,131,576		$	(460)		$	(650,646)			$	480,478
Stock-based compensation expense, including employee stock purchase plan expense				12,903									12,903
Issuance of shares under employee stock purchase plan	62,778				652									652
Exercise of stock options	56,417				218									218
Net unrealized loss on marketable securities							(487)						(487)
Net loss										(63,200)			(63,200)
Balances at June 30, 2026	87,452,166	$	8	$		1,145,349		$	(947)		$	(713,846)			$	430,564
Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income (Loss) · Deficit · Equity
Balances at December 31, 2025	81,376,449	$	8	$		1,075,487		$	621		$	(597,557)			$	478,559
Exchange of pre-funded warrants for common stock shares	3,500,000												—
Issuance of shares under at-the-market offering, net of issuance costs of $25	1,712,739				41,918									41,918
Stock-based compensation expense, including employee stock purchase plan expense				23,051									23,051
Exercise of stock options	800,200				4,241									4,241
Issuance of shares under employee stock purchase plan	62,778				652									652
Net unrealized loss on marketable securities							(1,568)						(1,568)
Net loss										(116,289)			(116,289)
Balances at June 30, 2026	87,452,166	$	8	$		1,145,349		$	(947)		$	(713,846)			$	430,564

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.